New Treatment for Psoriasis: Therapeutic Efficiency in Patients and Antiinflammatory Effect in Vitro

Ignacio Umbert1,3,*, Leonardo Márquez-Kisinousky4,5, Consol Farrera2, Jordi Valls1, Annabel Valledor2 and Laura Fernández-Fernández3

1Barcelona Skin Genomic SL, Barcelona, Spain
2Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Spain
3Instituto de Dermatología Ignacio Umbert Plaza Manuel Corachán 4, Barcelona, Spain
4Medical Science Consulting, Gijón, Spain
5Department of Brain Ischemia and Neurodegeneration, Barcelona Institute for Biomedical Research (IIBB) -Higher Council for Scientific Research (CSIC), Barcelona, Spain

Submission: May 27, 2020; Published: June 09, 2020

*Corresponding author: Ignacio Umbert, Barcelona Skin Genomic SL and instituto de Dermatología Ignacio Umbert Plaza Manuel Corachán 4, Barcelona, Spain

Abstract

Background: Psoriasis is a worldwide chronic inflammatory disease that is increasingly being considered as a systemic disorder. Antioxidant and anti-inflammatory molecules have been revealed as potential adjuvants for traditional therapies.

Objectives: To evaluate the anti-inflammatory action of selected antioxidant molecules and their beneficial effect as combination therapy in psoriatic patients.

Materials & Methods: Thirty-five patients with mild (five), moderate (nine) and severe (twenty one) psoriasis were selected and treated with EP2311454 treatment. PASI, BSA and DLQI assessed the severity of psoriasis and the impact on quality of life. The anti-inflammatory effect was tested in IFN-γ stimulated Raw264.7 macrophages that express human PPARG.

Results: The combined use in vitro of several EP2311454 components exerts a synergistic inhibitory effect on the expression of the pro-inflammatory mediators Cox2, Nos2 and Cxcl9. Clinically, more than 80% reduction in DLQI levels is observed after treatment, and 100% of severe patients achieved PASI 75 and significant reduction of BSA levels after 15 days of treatment.

Conclusion: EP2311454 treatment, composed by antioxidant molecules, proved to be anti-inflammatory in vitro and showed efficacy in patients with mild to severe psoriasis, as demonstrated by a significant decrease in PASI, BSA and DLQI levels.

Keywords: Antiinflammatory; Antioxidant; Psoriasis Treatment

Introduction

Psoriasis is a chronic inflammatory disease with predominant skin and joint involvement and a worldwide distribution affecting both sexes, of any age, but more frequently in the 3rd and 4th decades of life [1]. The disease is characterized by disfiguring scaling and erythematos plaques. The severity of psoriasis is defined by the clinical form, the proportion of body surface area affected and the severity of the symptoms. Psoriatic plaques may be painful and often severely pruritic, causing a deterioration in the quality of life [2]. Medical therapy for psoriasis has classically included topical and systemic treatments such as phototherapy, retinoids, methotrexate, and cyclosporine [3]. In the last few years, biologic treatment has become the established therapeutic standard for significant improvement of the quality of life of patients with moderate to severe psoriasis [4]. The involvement of oxidative stress in the pathogenesis of psoriasis has been recently proposed. Oxidative stress is an imbalance between...
oxidents and antioxidants in favour of the oxidants, leading to a disruption of redox signalling and promoting molecular damage [5]. Different studies have associated the antioxidant properties of specific compounds with anti-inflammatory effects in psoriasis, suggesting a potential role for these compounds as therapeutic tools [6,7]. Using well characterized compounds, the “Ignacio Umbert Dermatology Institute” (IUDI) has developed topical treatments that differ from the standards. The therapy used for psoriasis (European patent number EP2311454) is a combination of well-established drugs and a set of compounds with antioxidant activity (indomethacin, acsorbil palmitate, taurine, curcumin and resveratrol), whose anti-inflammatory effects were tested in vitro in this study.

Methods

Cell culture

Raw264.7 macrophages (American Type Culture Collection, Manassas, VA, USA) were used for the in vitro analysis of the anti-inflammatory activity of specific compounds. Raw264.7 cells were stably transfected with a mammalian expression vector encoding human peroxisome proliferator-activated receptor-gamma (PPARG). Cell transfection was performed using Superfect reagent (Qiagen, Valencia, CA, USA) following the manufacturer’s recommendations. Two days after transfection, stable transfectants were selected by culturing the cells for two weeks in DMEM (Biowest, Nuaille, France) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Biosera, Boussens, France) and geneticin (Thermo Fisher Scientific, Rockford, IL, USA). A clone of cells was selected and the expression of human PPARG was verified by both quantitative real time-PCR and by western blotting using rabbit polyclonal antibodies against hPPARG (Cell Signaling, Danvers, MA, USA).

Treatment: Interferon-gamma (IFN-γ) was obtained from Thermo Fisher Scientific (Rockford, IL, USA). Indomethacin, acsorbil palmitate, taurine, curcumin and resveratrol are the main components of EP2311454 treatment (EP2311454 patent). Ascorbic acid 6-palmitate was purchased from Abcam (Cambridge, UK) and the rest of compounds were obtained from Sigma-Aldrich (Saint Louis, MO, USA). All of them were dissolved according to the manufacturer’s instructions. Treatment of Raw 264.7 cells with antioxidant compounds and/or IFN-γ was performed in DMEM supplemented with 1% heat-inactivated FBS.

Determination of gene expression: Cells were washed twice in cold PBS and total RNA was extracted using TRI reagent (Sigma-Aldrich) as recommended by the manufacturer. For cDNA synthesis, 1μg of total RNA was subjected to reverse transcription using M-MLV Reverse transcriptase RNase H Minus, Point Mutant, oligo(dT)15 primer and PCR nucleotide mix (Promega, Fitchburg, WI, USA). Quantitative real time (rt)-PCR was performed using the Power SYBR Green Reagent Kit (Applied Biosystems, Foster City, CA) following the manufacturer’s recommendations. The primers used in this study are shown in (Table 1). Annealing for all primers was performed at 60°C for 30s. Real-time monitoring of PCR amplification was performed using the ABI Prism 7900 Sequence Detection System (Applied Biosystems). Data were expressed as relative mRNA levels normalized to ribosomal L14 expression.

Table 1: Primers used for quantitative real-time-PCR determinations.

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Forward primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cxcl9</td>
<td>5′-GGAGTTGGAGGAACCTCTAGG-3′</td>
<td>5′-GGGATTGTAGTGATCGTGAG-3′</td>
</tr>
<tr>
<td>L14</td>
<td>5′-TCCCCGGCTGTTAACGCCAGG-3′</td>
<td>5′-GGGATGACCTCGCAGCC-3′</td>
</tr>
<tr>
<td>Nos2</td>
<td>5′-GCCACCAACATGAGCAGCA-3′</td>
<td>5′-CTGAGGATGAGCTGAATGTT-3′</td>
</tr>
<tr>
<td>Cox2</td>
<td>5′-ATCTCTTGGCCGAGCTTTCA-3′</td>
<td>5′-GGGATGACACTTCCGACCAA-3′</td>
</tr>
</tbody>
</table>

Human study

Selection: A group of 35 patients, (5 mild, 9 moderate and 21 severe psoriasis) both males and females, previously diagnosed with psoriasis were included in the study. Patients were eligible to participate in the trial if they were at least 18 years of age and had been diagnosed with mild to severe psoriasis. Individuals with allergies or pregnant women were not included in the study. Patients provided written, informed consent.

Monitoring: For evaluation, a total of six visits were planned at 0, 15, 30, 45, 52 and 60 days from the start of treatment. Photographs were taken and physical and dermatological examinations were performed.

Treatment: Patients were instructed to use 2 g of cream per application and perform three applications per day (every 8h). The cream was placed first on the fingertips and then distributed homogeneously in small sub-portions on the affected area. Circular motions were performed until the cream was completely absorbed by the skin. In addition, 0.5 g curcumin per day was administered orally dissolved in soups.

Evaluation: The effectiveness of the therapy on disease severity was scored using two objective outcome measurements, namely Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA). PASI was calculated for all patients. Each site (head, trunk, upper and lower limbs) was evaluated separately for erythema, infiltration and desquamation and the data were summed to calculate final PASI, as described previously (“Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis” European Medicines Agency Evaluation of Medicines for Human Use, 2014). Additionally, the quality of life was measured
using the Dermatology Life Quality Index (DLQI). The following criteria was used to determine the severity of psoriasis: mild to moderate psoriasis: BSA < 10% or PASI < 10; moderate psoriasis: 10% < BSA > 20% or 10 ≤ PASI ≥ 20; severe psoriasis: BSA > 20% or PASI > 20. The efficacy of treatment was evaluated through PASI 75, which represents the percentage of patients achieving a 75% or more reduction in their PASI score from baseline.

**Statistical analysis**

Results are presented as mean ± SEM. GraphPad Prism program (Prism 4.0, Graphpad Software Inc) and SPSS software (IBM) were used for statistical analysis of the human and in vitro studies, respectively. In Figure 3, a two-tailed Student t-test was used for paired comparisons. Differences were considered significant if the p-value < 0.05.

**Results**

**Clinical evaluation of EP2311454 in psoriasis patients**

Patients treated with EP2311454 have a positive response to treatment; examples of target-lesions improvement are shown in Figure 1, in which the patients were recovered after 15 (Figure 1a) or 60 days (Figure 1b) of treatment. Quality of life before and after the treatment was assessed by determining the DLQI index and results indicate that EP2311454 improves the outcome. 95% of patients treated show significant amelioration of the disease, with an average reduction of 80% reduction in DLQI levels after 60 days of treatment (Figure 1c). Besides DLQI, two other parameters, PASI and BSA, were evaluated at baseline and at different time points after the start of treatment (0, 15, 30, 45 and 60 days). PASI values decreased significantly, with clear effects already at day 15 of treatment (Figure 2a). When taking into account global improvement, 100% of patients, including patients with moderate to severe psoriasis, achieved at least 50% improvement in PASI (PASI 50) (Figure 2b). Furthermore, the proportions of patients who achieved PASI 75 was 80% in the mild to moderate group and 100% in the severe group of patients. Interestingly, 70% of EP2311454-treated severe patients reached PASI 90 (Figure 2b). On the other hand, significant reduction of BSA values compared to baseline were also observed in patients treated with EP2311454 (Figure 2c).

![Figure 1: Progression of psoriatic lesions under EP2311454 treatment. a) Picture of the back of a patient with severe psoriasis before (left) and after (right) treatment. b) Picture of the arm of a moderate patient with psoriasis before (left) and after (right) treatment. c) DLQI levels pre and posttreatment, 60 days. Treatment reduces significantly DLQI levels n=22 ****p< 0.0001 versus pretreatment (paired Student t-Test).](image-url)
In vitro effects of EP2311454 components on macrophage activation by IFN-γ

Raw264.7 macrophages expressing human PPAR-γ were pretreated with different combinations of the antioxidant compounds in EP2311454 treatment and then stimulated with IFN-γ for 6h (Figure 3). Changes in gene expression were analyzed through quantitative rt-PCR (Figure 3a). The percentage of repression was calculated in order to compare the effectiveness of combinations of compounds (Figure 3b). In Figure 3b, positive values indicate repression (inhibition), whereas negative values indicate induction (increase) in comparison with the levels of expression in IFN-γ-treated cells. In these conditions, the combined use of curcumin and ascorbic acid 6-palmitate resulted in synergistic inhibitory effects on the expression of the enzymes cyclooxygenase 2 (Cox2) and nitric oxide synthase 2 (Nos2), and the chemokine Cxcl9, whereas the expression of tumor necrosis factor-alpha (Tnfa) and C-C motif chemokine ligand 2 (Ccl2/MCP-1) was unaffected (data not shown). Moreover, the use of indomethacin further enhanced the inhibitory effects of curcumin and ascorbic acid 6-palmitate on Nos2 and Cox2 expression.

Discussion

Given the limitations of current treatments for psoriatic diseases and the evidence that reactive oxygen species-mediated oxidative stress contributes to the pathogenesis of inflammatory skin disorders, including psoriasis [8,9], new approaches have been designed in the last few years based on the pharmacological use of antioxidant molecules, such as epigallocatechin-3-gallate [6] and curcumin [10]. Antioxidant compounds have demonstrated efficacy as therapeutical treatments also against other chronic inflammatory diseases [11]. Although the clinical application of antioxidants for skin inflammatory disorders is not widespread, we decided to test their efficacy in psoriasis using a combination of antioxidant compounds. In particular, EP2311454 combines compounds with both antioxidant and antiinflammatory activity and traditional drugs in order to ameliorate the symptoms of psoriasis. The main components in EP2311454 are resveratrol, taurine and ascorbyl-L-palmitate, previously defined as antioxidant compounds in humans, and indomethacin which is anti-inflammatory in low doses [12].
Figure 3: Effects of combined treatment with low doses of antioxidants. The cells were treated with IFN-γ (5 ng/ml) in the presence or absence of the indicated antioxidants: indomethacin (Indo, 5 µM), ascorbic acid 6-palmitate (Asc. Palm, 25 µM), and/or curcumin (10 µM). mRNA expression levels of several genes involved in the macrophage response to IFN-γ are represented a) The graphics show normalized values of gene expression relative to ribosomal L14 expression levels obtained from three to six independent experiments (depending on the gene studied). ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 versus IFN-γ. Two-tailed Student t-test. b) The % of repression of each combination of compounds (over the levels induced by IFN-γ was calculated for those genes whose expression was inhibited by one or more antioxidants.

EP2311454 treatment efficiency was evaluated in patients with psoriasis, resulting in significant decrease of BSA, DLQI and PASI levels. This analysis confirmed that EP2311454 is efficacious for the treatment of psoriasis. PASI 75 response rates for individuals treated with EP2311454 is 100% for severe patients and 80% for mild to moderate patients. The effect was evident at the earliest assessment (15 days). The results presented here are in line with other studies that suggested that moderate to severe psoriatic plaques should show a therapeutic response to orally administered curcuma [13] or to antioxidant compounds, pointing out that adjuvant therapies are promising solutions for increasing the efficacy of traditional drugs against psoriasis [14,15]. In order to understand the cellular mechanisms underlying the efficacy of EP2311454, the effects of individual and combined components within this formula were tested in a model of macrophage inflammatory response in vitro. Analysis of the combined action of indomethacin with other antioxidants has shown that the efficacy of some combinations is greater than the efficacy of individual compounds. The combined use of curcumin and ascorbic acid 6-palmitate resulted in synergistic inhibitory effects on the expression of Cox2, Nos2 and Cxcl9, and the presence of indomethacin in the combination further increased repression of Nos2 and Cox2. These results suggest that the combination of curcumin and ascorbic acid 6-palmitate together with indomethacin have increased anti-inflammatory capacity than the antioxidants individually. Together with the clinical results, these data suggest that EP2311454 treatment is a promising strategy to ameliorate the clinical symptoms of psoriasis.

References


